Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Janus kinase inhibitors

Decernotinib, Subcutaneous Methotrexate Drug Updates, Trials, Approvals

Michele B. Kaufman, PharmD, BCGP  |  October 1, 2014

Plus, rheumatology drug news, safety updates

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:drugFDAInjectionKaufmanMethotrexateResearchRheumatoid arthritisrheumatologistSafetyTofacitinib

ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?

Kathy Holliman  |  August 1, 2013

Experts highlight treatment advances and challenges ahead in OA, RA, and systemic lupus erythematosus (SLE)

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RLupusOsteoarthritisRheumatoid arthritisSLETreatment

Panel Addresses Drug Safety Issues in Rheumatology Products

Thomas R. Collins  |  February 15, 2013

Black box warnings, TNF inhibitors, and tofacitinib discussed

Filed under:Uncategorized Tagged with:FDAjanus kinase inhibitorTNF inhibitorsTofacitinib

Rheumatology Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  January 1, 2013

Information on new approvals and medication safety rheumatologists need to know

Filed under:Drug Updates Tagged with:adalimumabDrugsFDAguidelineSafety

Drug Updates: Citalopram hydrobromide, Statins, and More

Michele B. Kaufman, PharmD, BCGP  |  May 8, 2012

Information on new approvals and medication safety

Filed under:Drug Updates Tagged with:ApprovalsBiologicsdrugJAK inhibitorsjanus kinasePipelineRheumatoid arthritisSafetyStatin

ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

Vanessa Caceres  |  April 6, 2012

Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.

Filed under:ConditionsMeeting ReportsResearch RheumRheumatoid ArthritisSystemic SclerosisVasculitis Tagged with:ACR/ARHP Annual MeetingJAK inhibitorsjanus kinaseRAResearchRheumatoid arthritisrituximabSclerodermasclerosisTreatmentVasculitis

Information on New Drug Approvals and Medication Safety

Michele B. Kaufman, PharmD, BCGP  |  March 8, 2012

Rheumatology-related drug safety, approvals, and what’s in the pipeline.

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryBiologicscrystal arthritisdrugGoutJAK inhibitorsjanus kinaseMethotrexateRheumatoid arthritisrheumatologistSafetyTofacitinib

Opening a New Therapeutic Window for Rheumatoid Arthritis

Ann Kepler  |  January 13, 2012

New targets in rheumatoid arthritis: SYK, JAK, BTK

Filed under:Biologics/DMARDsConditionsDrug UpdatesMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR/ARHP Annual Meetinganti-inflammatoryBiologicsdrugImmunologyJAK inhibitorsjanus kinasepatient careResearchRheumatoid arthritis

Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  May 16, 2011

Information on New Approvals and Medication Safety

Filed under:AnalgesicsDrug Updates Tagged with:ApprovalsDrugsFDAPipelineSafetyshortage

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences